Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer.

Gary N Schwartz Peter A Kaufman Karthik V Giridhar Jonathan D Marotti Mary D Chamberlin Bradley A Arrick Grace Makari-Judson Matthew P Goetz Shannon M Soucy Fred Kolling Iv Eugene Demidenko Todd W Miller

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Alternating 17β-estradiol/AI therapy may be a promising treatment for endocrine-refractory ER+ breast cancer, including following progression on CDK4/6 inhibitors or everolimus. Further study is warranted to determine whether the antitumor activity of 17β-estradiol differs according to ESR1 mutation status.

Keyphrases

estrogen receptor
breast cancer risk
artificial intelligence
cell cycle
bone mineral density
stem cells
deep learning
cell therapy